Rasna Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, with a research and development team located in Doylestown, Pennsylvania. Founded in 2013, the company is focused on developing therapeutics to address the high unmet need for acute myeloid leukemia (AML) and other forms of leukemia. Their primary indication is AML, a rapidly progressing and potentially fatal blood cancer with a low survival rate. Rasna Therapeutics aims to improve the safety and efficacy of current AML combination therapies through their clinical programs targeting key regulators of cancer.
With two lead programs in the clinic, Rasna Therapeutics is dedicated to developing novel interventions for AML. Their RASP-201 targets LSD1, a pathway that blocks differentiation and confers a poor prognosis in AML, while RASP-301 focuses on NPM1, a potential treatment for refractory AML with reduced toxicity. By leveraging the expertise of their experienced industry team and leading scientists, Rasna Therapeutics is committed to making a significant impact in the field of leukemia therapeutics.
Generated from the website
